Inhibition of p53 expression decreases TRAIL receptor-induced apoptosis. by Anna Willms (6556340)

Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome by Giray Bozkaya (8739405)

IL-10 production in response to IL-27 is impaired in Chagas disease patients with severe cardiomyopathy. by María Ailén Natale (6843422)

Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? by Isa Sincer (7234577)

“…Methods: 70 patients with normal coronary arteries and 50 with coronary artery fistulas were included. …”

Effects of Nogo-A and its receptor on the repair of sciatic nerve injury in rats by Junjie Jiang (7255706)

Bone histomorphometry at baseline and at the end of follow-up. by Lucas L. A. Nunes (19360381)

Source data for Fig 1. by Rahsan Erdem (11726357)

Source data for Fig 2. by Rahsan Erdem (11726357)

Source data for Fig 3. by Rahsan Erdem (11726357)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Fig 4 - by Lucas L. A. Nunes (19360381)

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Turnover, Mineralization, and Volume (TMV) classification at the different timepoints. by Lucas L. A. Nunes (19360381)

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Laboratory parameters and bone mineral density before and after 12 months after DFO. by Lucas L. A. Nunes (19360381)

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Turnover, Mineralization, and Volume (TMV) classification at baseline and 12 months after treatment with DFO. by Lucas L. A. Nunes (19360381)

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)